Detailed information on the current drug pipeline. This report provides insight into the pipeline status of thrombosis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Analysis of the competitive landscape and the recent changes in antihypertensives across seven major markets. Analysis of the threats to currently marketed drugs. Assessment of the opportunity available to novel agents, including Novartis’s Tektu

Datamonitor expects the cardiovascular market to remain stable with sales only showing negligible growth between 2006 and 2016, below the 3% growth predicted for the SU sold. Generic products will become increasingly important as the majority of produc

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of arrhythmiasis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of anemia drugs by company and by stage as well as a summary of the latest news and developments in this area.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of peripheral vascular disease drugs by company and by stage as well as a summary of the latest news and developments in this area.

Advanced heart failure is a growing issue. Existing pharmacological strategies increase the survival rates of acute heart failure patients, providing a growing source of patients with advanced disease. In view of long waiting lists for heart transplant

The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. Chapter 6 outlines future cardiovascular market trends and major growth opportunities. The d

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of ischemia drugs by company and by stage as well as a summary of the latest news and developments in this area.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of intermittent claudication drugs by company and by stage as well as a summary of the latest news and developments in this area.

Analysis of the acute and chronic heart failure pipeline across seven major markets.

An assessment of the current status of the cardiovascular market in terms of innovation and pipeline products with novel mechanism of action. Includes a status report for stem cell and gene therapies for cardiovascular medicine.

Stroke is one of the top three leading causes of death worldwide and an area of high unmet needs. TPA is limited to a low number of ischemic stroke patients due to a short therapeutic time window, but it is still the best therapy available. TPA is resp

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of angina drugs by company and by stage as well as a summary of the latest news and developments in this area.

Peripheral artery disease, sometimes also referred to as peripheral vascular disease, is atherosclerosis in peripheral regions, which can lead to loss of blood flow to the limbs, and can result in loss of life, limb amputation and cardiovascular events

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of thromboembolism drugs by company and by stage as well as a summary of the latest news and developments in this area.

In-depth review of developmental drugs for the acute stroke market. Explores the commercial prospects of new agents against existing products and profiles unmet market needs as well as unmet clinical needs, and provides sales forecasts to 2017.

This report will analyse the future potential of new and emerging products from the medical device, pharmaceutical and biotechnology sectors, and measure their likely impact upon the existing market.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of stroke drugs by company and by stage as well as a summary of the latest news and developments in this area.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of congestive heart failure drugs by company and by stage as well as a summary of the latest news and developments in this area.

This report provides full analysis of the current and future fibromyalgia market, with indication-specific forecasts to 2017 of branded, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).